Addressing overweight and obesity: Evolving to a medical consensus

Journal of the American Osteopathic Association

Volumn 108, Issue 2 SUPPL. 1, 2008, Pages

  Schaller, Frederick A ^a  

^a TOURO UNIVERSITY NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANANDAMIDE; ANGIOTENSINOGEN; ANTIOBESITY AGENT; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ; ENDOCANNABINOID; FIBRINOGEN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORADRENALIN; PEPTIDE YY; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; SEROTONIN; SERUM AMYLOID A; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ATHEROSCLEROSIS; BARIATRIC SURGERY; BILIARY TRACT DISEASE; BILIOPANCREATIC BYPASS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUING EDUCATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GALLBLADDER DISEASE; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEALTH CARE PERSONNEL; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHALAMUS; INSULIN RESISTANCE; LEUKOCYTE COUNT; LIFESTYLE MODIFICATION; LONGEVITY; MENTAL DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OSTEOARTHRITIS; PANCREAS DISEASE; PANCREAS INSUFFICIENCY; PATIENT EDUCATION; PROTEINURIA; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SMOKING; STOMACH BYPASS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UROGENITAL TRACT DISEASE; WAIST CIRCUMFERENCE; WHITE ADIPOSE TISSUE;

EID: 50449090485     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Centers for Disease Control and Prevention. Health, United States, 2006 With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2006. Available at: www.cdc.gov/nchs/ data/hus/hus06.pdf. Accessed January 31, 2008.
2. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79. Available at: http://jama.ama-assn.org/cgi/content/ full/289/1/76. Accessed January 23, 2008.
3. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007;132:2087-2102.
4. Kimm SY, Glynn NW, Kriska AM, Barton BA, Kronsberg SS, Daniels SR, et al. Decline in physical activity in black girls and white girls during adolescence. N Engl J Med. 2002;347(10):709-715. Available at: http://content.nejm. org/cgi/content/abstract/347/10/709. Accessed January 23, 2008.
5. Haas JS, Lee LB, Kaplan CP, Sonneborn D, Phillips KA, Liang SY. The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health. 2003;93:2105-2110. Available at: http://www.ajph.org/cgi/content/ full/93/12/2105. Accessed January 23, 2008.
6. US Department of Health and Human Services. The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity. Rockville, Md: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001. Available at: http://www.surgeongeneral.gov/topics/ obesity/calltoaction/CalltoAction.pdf. Accessed January 28, 2008.
7. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187-193. Available at: http://jama.amaassn.org/cgi/content/full/289/2/187. Accessed January 23, 2008.
8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Statistics Related to Obesity and Overweight. Bethesda, Md: National Institutes of Health; June 2007. NIH Publication No. 96-4158.
9. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481-486. Available at: http://www.annals.org/cgi/content/full/122/7/ 481. Accessed January 23, 2008.
10. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-969.
11. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J. 2005;149:54-60.
12. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355:763-778. Available at: http://content.nejm.org/cgi/content/abstract/355/8/763. Accessed January 28, 2008.
13. Deckelbaum RJ, Williams CL. Childhood obesity: the health issue[review]. Obesity Res. 2001;9 (suppl 4):239S-243S. Available at: http://www.obesityresearch.org/cgi/content/full/9/suppl_4/S239. Accessed January 28, 2008.
14. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood) . 2003;suppl Web exclusives: W3-219-226. Available at: http://content.healthaffairs.org/cgi/content/full/hlthaff.w3.219v1/DC1. Accessed January 28, 2008.
15. Centers for Disease Control and Prevention. US Obesity Trends 1985-2006. Available at: www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/. Accessed January 31, 2008.
16. Centers for Disease Control and Prevention. Diabetes and Gestational Diabetes Trends Among Adults in the United States. Available at: www.cdc.gov/diabetes/statistics/maps. Accessed January 31, 2008.
17. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System. Available at: http://apps.nccd.cdc.gov/gisbrfss/ select_question.aspx. Accessed October 5, 2007.
18. Dorland's Illustrated Medical Dictionary. 31st ed. Philadelphia, Pa: WB Saunders Co; 2007.
19. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring). 2006;14(suppl 5):242S-249S. Available at: http://www. obesityresearch.org/cgi/content/full/14/suppl_5/242S. Accessed January 28, 2008.
20. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones [review]. Clin Sci (Lond). 2006;110:143-152. Available at: http://www.clinsci.org/cs/110/0143/cs1100143.htm. Accessed January 28, 2008.
21. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue [review]. Br J Nutr. 2004;92:347-355. Available at: http://journals.cambridge.org/action/display-Fulltext?type=6&fid= 915808&jid=&volumeId=&issueId=03&aid=915804&fulltextType= RA&fileId=S0007114504001795. Accessed January 28, 2008.
22. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ [review]. J Clin Endocrinol Metab. 2004;89:2548-2556. Available at: http://jcem.endojournals.org/cgi/content/full/89/6/2548. Accessed January 28, 2008.
23. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism [review]. Am J Clin Nutr. 2006;83(suppl):461S-465S. Available at: http://www.ajcn.org/cgi/content/full/83/ 2/461S. Accessed January 28, 2008.
24. Bray GA. Medical consequences of obesity [review]. J Clin Endocrinol Metab. 2004;89:2583-2589.Available at: http://jcem.endojournals.org/cgi/ content/full/89/6/2583. Accessed January 2008.
25. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200. Available at: http://endo.endojournals.org/cgi/content/full/144/6/2195. Accessed January 28, 2008.
26. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337-350.
27. Farooqi IS, Matarese G, Lord GM, Lawrence E, Agwu C, Sanna V, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093-1103.
28. Huerta MG. Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes? Rev Endocr Metab Disord. 2006;7:187-196.
29. Shamsuzzaman ASM, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation. 2004;109:2181-2185. Available at: http://circ.ahajournals.org/cgi/content/full/109/18/2181. Accessed January 28, 2008.
30. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295. Available at: http://www.nature.com/nm/journal/v8/n11/full/nm788.html. Accessed January 28, 2008.
31. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947-953. Available at: http://www.nature.com/nm/journal/v7/n8/full/nm0801_947.html. Accessed January 28, 2008.
32. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MRS, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA. 2001;98:2005-2010. http://www.pnas.org/cgi/content/full/ 98/4/2005. Accessed January 28, 2008.
33. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935. Available at: http://jcem.endojournals.org/cgi/content/full/ 86/5/1930. Accessed January 28, 2008.
34. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769. Available at: http://jcem.endojournals.org/cgi/content/full/ 87/6/2764. Accessed January 28, 2008.
35. Rega G, Kaun C, Weiss TW, Demyanets S, Zorn G, Kastl SP, et al. Inflammatory cytokines interleukin-6 and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation. 2005;111:1938-1945. Available at: Accessed http://circ.ahajournals.org/cgi/ content/full/111/15/1938. January 28, 2008.
36. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334. Available at: http://jama.amaassn.org/cgi/content/full/286/3/ 327. Accessed January 28, 2008.
37. Rega G, Kaun C, Demyanets S, Pfaffenberger S; Rychli K, Hohensinner PJ, et al. Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin M in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol. 2007;27:1587-1595. Available at: http://atvb.ahajournals.org/cgi/content/full/ 27/7/1587. Accessed January 28, 2008.
38. Summers LK. Adipose tissue metabolism, diabetes and vascular disease - lessons from in vivo studies. Diabetes Vasc Dis Res. 2006;3(1):12-21. Available at: Accessed http://www.dvdres.com/pdf/2397/Vol3_Num1_May_2006_p12-21. pdf. January 28, 2008.
39. Kozek E, Katra B, Malecki M, Sieradzki J. Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation. Rev Diabet Stud. 2004;1(3):122-128. Available at: http://www.socbdr.org/content/e4/e887/volRdsVolumes888/issRdsIssues1034/ chpRdsChapters1092/strRdsArticles1093/index_en.html?showfulltext=1. Accessed January 28, 2008.
40. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine. 2006;29(1):81-90.
41. Pereira FO, Frode TS, Medeiros YS. Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediators Inflamm. 2006;2006(1):39062.
42. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update {review]. Clin Endocrinol (Oxf). 2006;64:355-365.
43. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? [review]. Int J Biochem Cell Biol. 2003;35:807-825.
44. Roth J, Qiang X, Marbán SL, Redelt H, Lowell BC. The obesity pandemic: where have we been and where are we going? Obesity Res. 2004;12 (suppl 2):88S-101S. Available at: http:// www.obesityresearch.org/cgi/content/ full/12/suppl_2/88S. Accessed January 28, 2008.
45. Ahima RS. Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity (Silver Spring). 2006;14(suppl 1):9S-15S. Available at: http://www.obesityresearch.org/cgi/content/full/14/suppl_1/9S. Accessed January 28, 2008.
46. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428.
47. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003;107:448-454. Available at: http://circ.ahajournals.org/ cgi/content/full/107/3/448. Accessed January 28, 2008.
48. Singhal A. Endothelial dysfunction: role in obesity-related disorders and the early origins of CVD. Proc Nutr Soc. 2005;64(1):15-22. Available at: http://journals.cambridge.org/action/displayFulltext?type=6&fid= 902356&jid=&volumeId=&issueId=01&aid=902352&fulltextType= MR&fileId=S0029665105000030. Accessed January 29, 2008.
49. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring). 2006;14(suppl 3):143S-149S. Available at: http://www. obesityresearch.org/cgi/content/full/14/suppl_3/143S. Accessed January 28, 2008.
50. Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Bátkai S,et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053-3060. Available at: http://diabetes.diabetesjournals.org/cgi/ content/full/55/11/3053. Accessed January 28, 2008.
51. Fride E. The endogenous cannabinoid system: a new player in the brain-gut-adipose axis. Cannabinoids. 2007;2(2):5-12. Available at: http://209.85.173.104/search?q=cache:ZrNDaX64094J:www.cannabis-med.org/english/ journal/en_2007_02_1.pdf+The+endogenous+cannabinoid+system: +a+new+player+in+the+brain-gut-adipose+axis&hl=en&ct=clnk&cd= 1&gl=us. Accessed January 28, 2008.
52. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva, S, Liu J, Harvey-White J, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110(14):1996-2002. Available at: http://circ.ahajournals.org/cgi/content/ full/110/14/1996. Accessed January 28, 2008.
53. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev. 2007;23:507-517.
54. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550-557. Available at: http://www.nature.com/bjp/ journal/v136/n4/full/0704767a.html. Accessed January 28, 2008.
55. Iverson L. Cannabis and the brain. Brain. 2003;126:1252-1270. Available at: http://brain.oxfordjournals.org/cgi/content/full/126/6/1252. Accessed January 28, 2008.
56. Gómez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002;22:9612-9617. Available at: http://www.jneurosci.org/cgi/content/full/22/ 21/9612. Accessed January 28, 2008.
57. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298-1305.
58. Horvath TL. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest. 2003;112:323-326. Available at: http://www.jci.org/articles/view/19376. Accessed January 28, 2008.
59. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63:908-914. Available at: http://molpharm.aspetjournals.org/cgi/content/full/63/4/908. Accessed January 28, 2008.
60. ob mice. Int J Obes. 2005;29:183-187.
61. 1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28(4):640-648.
62. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab. 2005;7 (1):65-72.
63. Matsumoto H, Nakao T, Okada T, Nagaoka Y, Iwasawa H, Tomaru R, et al. Insulin resistance contributes to obesity-related proteinuria. Intern Med. 2005;44:548-553. Available at: http://www.jstage.jst.go.jp/article/ internalmedicine /44/6/548/_pdf. Accessed January 28, 2008.
64. Blankfield RP, Hudgel DW, Tapolyai AA, Zyzanski SJ. Bilateral leg edema, obesity, pulmonary hypertension, and obstructive sleep apnea. Arch Intern Med. 2000;160:2357-2362. Available at: http://archinte.ama-assn.org/cgi/ content/full/160/15/2357. Accessed January 28, 2008.
65. Pi-Sunyer FX, Becker DM, Bouchard C, et al. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, Md: National Institutes of Health; 1998. NIH Publication No. 98-4083.
66. Bouchard C, Després JP, Mauriége P. Genetic and nongenetic determinants of regional fat distribution. Endocr Rev. 1993;14(1):72-93. Available at: http://edrv.endojournals.org/cgi/reprint/14/1/72. Accessed January 28, 2008.
67. Challis BG, Yeo GSH. Past, present and future strategies to study the genetics of body weight regulation. Brief Funct Genomic Proteomic. 2002;1:290-304. Available at: http://bfgp.oxfordjournals.org/cgi/reprint/1/3/ 290. Accessed January 28, 2008.
68. Després JP, Lemieux I, Purd'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322:716-720. Available at: http://www.bmj.com/cgi/content/full/322/7288/716. Accessed January 28, 2008.
69. Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30:1647-1652. Available at: http://care.diabetesjournals.org/cgi/content/full/30/6/1647. Accessed January 28, 2008.
70. Assmann G, Carmena R, Cullen P, Fruchart JC, Jossa F, Lewis B, et al. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease. Circulation. 1999;100:1930-1938. Available at: http://circ.ahajournals.org/cgi/content/full/ 100/18/1930. Accessed January 28, 2008.
71. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. Available at: http://circ.ahajournals.org/cgi/content/full/107/3/499. Accessed January 28, 2008.
72. Brooks NL, Moore KS, Clark RD, Perfetti MT, Trent CM, Combs TP. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome? Diabetes Obes Metab. 2007;9:246-258.
73. Beckley ET. New ADA initiative moves beyond 'metabolic syndrome.' DOC News. 2006;3(7). Available at: http://docnews.diabetesjournals.org/cgi/ content/full/3/7/1. Accessed January 31, 2008.
74. Virani SS, Nambi V. The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis. Curr Atheroscler Rep. 2007;9:97-103.
75. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al; for the Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
76. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-761.
77. The National Heart, Lung, and Blood Institute, and the North American Association for the Study of Obesity. The Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, Md: National Institutes of Health; October 2000. NIH Publication Number 00-4084. Available at: http://209.85.173.104/search?q=cache: Dw1DtoWJIngJ:www.nhlbi.nih.gov/guidelines/obesity/prctgd_c. pdf+The+Practical+Guide+to+the+Identification,+Evaluation, +and+Treatment+of+Overweight+and+Obesity+in+Adults&hl=en&ct=clnk&cd= 2&gl=us. Accessed January 28, 2008.
78. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al; American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-172. Available at: http://care.diabetesjournals.org/cgi/content/full/30/1/162. Accessed January 29, 2008.
79. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
80. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. Available at:http://circ.ahajournals.org/cgi/content/full/112/17/2735. Accessed January 16, 2008.
81. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111-2120. Available at: http://content.nejm.org/cgi/ content/full/353/20/2111. Accessed January 29, 2008.
82. Li Z, Maglione M, Tu W, Arterburn D, Shugarman LR, Hilton L, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546. Available at: http://www.annals.org/cgi/content/full/142/7/ 532. Accessed January 29, 2008.
83. Yanovski SZ, Yanovski JA. Obesity [review]. N Engl J Med. 2002;346:591-602.
84. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119-2125.
85. James WP. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J. 2005;7(suppl L):L44-L48.
86. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al; on behalf of the SCOUT investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007;28:2915-2923. Available at: http://eurheartj. oxfordjournals.org/cgi/content/full/28/23/915. Accessed January 29, 2008.
87. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161. Available at: http://care.diabetesjournals.org/cgi/content/full/27/1/155. Accessed January 29, 2008.
88. Didangelos TP, Thanopoulou AK, Bousboulas SH, Sambanis CL, Athyros VG, Spanou EA,et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) study. Curr Med Res Opin. 2004;201:393-1401.
89. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Rosenstock J; for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-775.
90. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547-559. Available at: http://www.annals.org/cgi/content/full/142/7/ 547. Accessed January 29, 2008.
91. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-1737. Available at: http://jama.amaassn.org/cgi/content/full/292/ 14/1724. Accessed January 29, 2008.
92. Nguyen NT, Silver M, Robinson M, Needleman B, Hartley G, Cooney R, et al. Result of a national audit of bariatric surgery performed at academic centers: a 2004 University HealthSystem Consortium benchmarking project. Arch Surg. 2006;141:445-450. Available at: http://archsurg.amaassn.org/cgi/ content/full/141/5/445. Accessed January 29, 2008.
93. Bardia A, Holtan SG, Slezak JM, Thompson WG. Diagnosis of obesity by primary care physicians and impact on obesity management. Mayo Clin Proc. 2007;82:927-932.
94. US Department of Health and Human Services. Reducing Tobacco Use: a Report of the Surgeon General. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health; 2000. Available at: http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2000/ sgr_tobacco_chap.htm.Accessed October 19, 2007.
95. Mercer SL, Green LW, Rosenthal AC, Husten CG, Khan LK, Dietz WH. Possible lessons from the tobacco experience for obesity control. Am J Clin Nutr. 2003;77(suppl):1073S-1082S. Available at: http://www.ajcn.org/cgi/content/full/ 77/4/1073S. Accessed January 29, 2008.